

**Nucleix – Using Epigenetics for Cancer Detection in Liquid Biopsy**  
**Dr. Elon Ganor, Nucleix**

**Questions for Biotech/Pharma; Medical Devices and Health IT/Digital Health categories are:**

○ **Investment Rational**

Briefly describe the company's technology or therapeutic focus. The market opportunity, progress made to date key partnerships or joint ventures. Management strengths

Nucleix develops, manufactures and markets highly innovative and non-invasive molecular cancer diagnostic tests. With the huge unmet need for early detection of cancer and superior product performance, Nucleix's target market is a several billion dollar market. Nucleix are supported by leading KOLs in their fields and have a highly experienced and diversified management team to successfully implement in the market.

○ **Business Strategy**

Briefly describe how the company will apply its core technology, Generate near-term and long term revenues

Nucleix's technology provides a unique commercial position as it produces best-in-class products. Nucleix have recently started to commercialize through top distributors and large laboratory chains in Europe, and will be followed in North-America and other relevant territories.

○ **Core Technology**

What is the technology, its uniqueness and its value proposition

Our highly sensitive and specific tests are based on identification of subtle changes in methylation patterns in liquid biopsy samples (such as blood or urine). Nucleix's technology is based on a combination of a new biochemical platform in conjunction with sophisticated bioinformatics techniques and algorithms, which allows it to develop biomarker panels with superior performance.

○ **Product Profile/Pipeline**

Describe companies' product/pipelines, current status and market potential. Discuss milestones, potential collaboration and partnership

Bladder EpiCheck is a CE-Marked non-invasive product for bladder cancer monitoring in urine samples. It includes a panel of 15 biomarkers, and was validated in several clinical studies in leading urology centers in Europe. Results show superior performance over other lab tests.

Lung EpiCheck (in development) is a lung cancer screening test developed with similar technology and has very promising initial results.

○ **What's Next?**

R&D + Preclinical / Clinicals

- Validation of Bladder EpiCheck in the US for the US FDA (ongoing clinical study)
- Initial validation and optimization of Lung EpiCheck in cooperation with several European and Israeli centers